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ABSTRACT
Estrogen Receptor alpha (ER`) activation by estrogenic hormones induces 
luminal breast cancer cell proliferation. However, ER` plays also important hormone-
independent functions to maintain breast tumor cells epithelial phenotype. We 
reported previously by RNA-Seq that in MCF-7 cells in absence of hormones ER` down-
regulation changes the expression of several genes linked to cellular development, 
representing a specific subset of estrogen-induced genes. Here, we report regulation 
of long non-coding RNAs from the same experimental settings. A list of 133 Apo-
ER`-Regulated lncRNAs (AER-lncRNAs) was identified and extensively characterized 
using published data from cancer cell lines and tumor tissues, or experiments on 
MCF-7 cells. For several features, we ran validation using cell cultures or fresh tumor 
biopsies. AER-lncRNAs represent a specific subset, only marginally overlapping 
estrogen-induced transcripts, whose expression is largely restricted to luminal cells 
and which is able to perfectly classify breast tumor subtypes. The most abundant AER-
lncRNA, DSCAM-AS1, is expressed in ER`+ breast carcinoma, but not in pre-neoplastic 
lesions, and correlates inversely with EMT markers. Down-regulation of DSCAM-AS1 
recapitulated, in part, the effect of silencing ER`, i.e. growth arrest and induction of 
EMT markers. In conclusion, we report an ER`-dependent lncRNA set representing a 
novel luminal signature in breast cancer cells.
INTRODUCTION
Breast tumors of the luminal subtype expressing 
Estrogen Receptor alpha (ERα) represent a prominent 
part of breast cancers and are treated with anti-estrogenic 
drugs with good rate of success, albeit endocrine 
resistance is still difficult to detect and justifies failure 
in one-fourth of cases [1]. In addition to being the main 
mediator of estrogenic hormone action in breast cancer 
cells, ERα displays an estrogen-independent function 
in its unliganded status (Apo-ERα). The functions of 
ERα as well as of other nuclear receptors in absence of 
ligands have been exhaustively reviewed recently [2, 3] 
and are thought to depend on phosphorylation by several 
signal transducing kinases or on interaction with other 
Transcription Factors (TFs). In breast cancer cells cultured 
in absence of hormone, depletion of ERα brings about a 
response similar to Epithelial-to-Mesenchymal Transition 
(EMT) [4–6] by activating mesenchymal genes and 
growth-sustaining pathways and, in vivo, the loss of ERα 
is usually accompanied by a more invasive and clinically 
aggressive phenotype [7, 8]. Conversely, in some model 
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systems, it was shown that re-expression of ERα leads 
to the re-appearance of epithelial gene expression [5, 9]. 
Thus, together with other TFs such as Forkhead box 
protein A1 (FoxA1) and Activating enhancer binding 
Protein 2 γ (AP-2γ), the estrogen-independent activity of 
ERα seems important in maintaining the luminal epithelial 
phenotype and blocking EMT in breast cancer cells. It is 
noteworthy that a hormone-deprived environment is what 
is realized in breast cancer patients treated with Aromatase 
Inhibitors (AIs), the category of drugs that is becoming 
one of the most widely used for breast cancer patients 
with ERα+ tumors. In our previous work we have shown 
that unliganded ERα binds to thousands of chromatin 
sites and controls the basal transcription of genes linked 
to cell development and epithelial differentiation, which 
represent a specific subset of estrogen-induced genes [4]. 
Interestingly, among Apo-ERα-dependent genes a group 
of noncoding transcripts was observed. Long noncoding 
RNAs (lncRNAs) are increasingly recognized as an 
exceptionally interesting group of RNAs with regulatory 
functions. LncRNAs show a much higher degree of tissue- 
and cell-type specificity than protein-coding transcripts 
and systematic approaches to unravel their role have 
converged to indicate developmental functions [10–12]. 
In a number of cases, specific lncRNAs were reported 
as linked to human diseases, especially in cancer [13]. 
There are numerous reports testifying alterations of the 
expression levels of several lncRNAs in cancer [10, 13] 
and the involvement of lncRNAs as controllers of the 
availability of specific miRNAs [14]. In breast cancer, 
either aberrant expression or tumorigenic functions of a 
number of lncRNAs were reported [15, 16]. Analysis of 
lncRNAs expressed in breast cancer and their correlation 
with clinicopathological parameters are available from 
several studies [17–24] and possible roles in endocrine 
resistance suggested [1]. In addition, the noncoding 
response to estrogen stimulation in vitro has been 
extensively described using both RNA-Seq [16] and GRO-
Seq analysis in breast cancer cell lines [25–27].
We report here that in hormone-deprived conditions 
ERα controls the expression of 133 lncRNAs that 
are highly specific for luminal breast cancer and that 
consequently can be used as biomarkers of this specific 
subtype. In addition, we found that the most abundant of 
these lncRNAs, DSCAM-AS1, is highly specific to ERα+ 
luminal cells and correlates with a specific stage of breast 
cancer. Moreover, DSCAM-AS1 deletion can extensively 
mimic the effect of deleting ERα in breast cancer cells.
RESULTS
ERα down-regulation in absence of hormones 
defines a set of differentially expressed lncRNAs
In our previous work, we carried out Apo-ERα 
chromatin binding analysis as well as poly(A+)-RNA-Seq 
analysis of MCF-7 cells cultured in hormone-deprived 
media and transfected with ERα-specific double-stranded 
interfering RNA (siRNA), or control siRNA [4]. Starting 
from this RNA-Seq data, by integrating Differentially 
Expressed (DE) genes defined by three algorithms 
(DESeq, EdgeR and RegionMiner), and filtering out 
protein-coding genes, short transcripts (length minor 
than 200 bp) and pseudogenes, we have compiled a list 
of 133 Apo-ERα-dependent lncRNAs (AER-lncRNAs) 
(Figure 1A, Supplemental Table 1A).
The most represented biotypes were “antisense” 
and “lincRNA” (Figure 1A). Both classes showed levels 
of expression, measured as RPKM (reads per Kilobase 
transcript per million reads), significantly lower than 
protein-coding genes, as expected (Wilcoxon Rank-Sum 
p-value < 0.00001) (Figure 1B). In total, 86 lncRNAs were 
down-regulated and 47 up-regulated in siERα transfected 
cells as compared to control. Validation relative to four 
down-regulated and one up-regulated lncRNAs using 
qRT-PCR in MCF-7 cells cultured in hormone-deprived 
medium and transfected with ERα-specific siRNA or 
control siRNA is shown in Figure 1C, demonstrating 
consistency to what observed in RNA-Seq data.
Taking advantage of our previously published map 
of AERBS (“unliganded” or Apo-ERα Binding Sites) [4], 
we next asked if AER-lncRNAs also had evidence of ERα 
binding within their genomic domain (within ± 100 Kb 
from gene TSS) and evaluated the distance of the closest 
AERBS from lncRNA gene TSS. This analysis showed 
that lncRNAs that are down-regulated by ERα depletion 
display closer AERBS than a random set of lncRNAs of 
equivalent size and biotype (Wilcoxon Rank-Sum p-value 
< 0.00001) (Figure 1D). This was expected assuming that 
Apo-ERα has prevalent trans-activating effect on linked 
promoters. The majority of AERBS were distant from 
TSS of regulated lncRNA genes, suggesting that they 
represent enhancers. To address this point further, we took 
advantage of published TFs and histone Post-Translational 
Modifications (PTMs) ChIP-Seq data obtained on MCF-7 
cultured in hormone-deprived medium (i.e. treated with 
vehicle alone in experiments of 17β-estradiol-induction) 
(Supplemental Table 2), which corresponds to our basal 
condition. Mapping of this data clearly demonstrated 
that AERBS attributable to AER-lncRNAs show clear 
enhancer histone PTMs patterns (Supplemental Figure 
1A). In addition, binding of FoxA1, AP-2γ, Forkhead box 
protein M1 (FoxM1) and histone acetyltransferase p300 
in the ± 1 Kb region around AERBS illustrates not only 
their prevalent nature as enhancers, but also that they 
resemble closely the AERBS found within protein coding 
gene domains [4]. On the other side, histone PTMs at 
AER-lncRNA gene TSS clearly show promoter features, 
with high H3K4me3/H3K4me1 ratio (Supplemental 
Figure 1B).
ERα binding within the promoter region was 
observed in few cases, e.g. the DSCAM-AS1 and 
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LINC01016 genes. We measured Apo-ERα binding to 
these regions by ChIP-qPCR, in comparison to the well-
known estrogen-dependent TFF1 gene and to the lncRNA 
AP001057.1 gene, which has an AERBS close to TSS, 
albeit not promotorial (4.5 Kb upstream). In all cases, we 
could confirm ERα binding in cells cultured in hormone-
deprived medium (Figure 1E). Concordant decrease of 
Apo-ERα binding and lncRNAs transcription is evident 
upon ERα down-regulation (cf. Figures 1E and 1C), and 
this fact correlated with the decreased binding of the two 
pioneer factors FoxA1 and AP-2γ, as described previously 
(Figure 1F) [4].
Altogether, these results demonstrate that ERα 
controls lncRNA transcription in MCF-7 cells cultured in 
hormone-deprived media, and this is achieved in a very 
similar manner to that previously observed in the case of 
protein coding genes.
AER-lncRNAs dependence on ERα does not 
imply estrogen responsiveness
Next, we asked whether lncRNA genes regulated 
by Apo-ERα were also estrogen-responsive. For this 
comparison, we took in account only the transcripts that 
Figure 1: Features of Apo-ERα regulated lncRNAs (AER-lncRNAs). A. Fraction of down-regulated (blue) and up-regulated 
(red) lncRNAs in siERα- vs siCTR-transfected MCF-7 cells; in brackets details of biotypes are shown. “Other lncRNAs” includes few 
cases classified as “processed-transcript”, “sense intronic” and “sense overlapping” in the database. B. Box plot showing expression levels 
of protein coding, antisense, lincRNAs and “other” lncRNAs regulated by Apo-ERα, in terms of log10 RPKM (Reads Per Kilobase per 
Million mapped reads); ***p-value < 0.00001 and *p-value < 0.05. C. Quantitative evaluation by qRT-PCR of expression change of five 
AER-lncRNAs in siERα- vs siCTR-transfected MCF-7, (dark blue and dark red bars). Values are log2 FC (fold-change). **p-value < 0.01 
and *p-value < 0.05. For comparison, corresponding data from RNA-Seq are shown in the plot as light blue and light red bars. D. Box plot 
reporting the distance of most proximal AERBS (Apo-ERα Binding Site) from the TSS of differentially expressed genes. In the case of 
protein coding genes, a direct comparison between down-regulated (blue) and up-regulated (red) RNAs is shown. In the case of lncRNAs, 
due to the smaller number, calculation is made separately for down- (blue) and up-regulated (red) genes with a random set (Rd) of lncRNAs 
of the same size (white boxes). The red dashed line indicates a distance of 100 Kb; ***p-value < 0.0001. E. ChIP-qPCR analysis of ERα 
binding to DSCAM-AS1, LINC01016 and AP001057.1 AERBS-containing 5′-flanking regions in hormone deprived MCF-7 cells. The TFF1 
promoter was used as a positive control, whereas the region upstream to KCNQ1OT1 TSS, where no AERBS was identified, was selected 
as negative control (error bars are SD of four independent biological replicates); ***p-value < 0.001, **p-value < 0.01 and *p-value < 0.05. 
F. ChIP-qPCR analysis of AP-2γ and FoxA1 binding to DSCAM-AS1 and LINC01016 putative promoters upon ERα silencing in hormone 
deprived MCF-7 cells (error bars are SD of three independent biological replicates); **p-value < 0.01.
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are directly responsive to 17β-estradiol (E2) in MCF-7 
cells. We exploited three published GRO-Seq experiments 
[25–27] and found that only 31 out of 133 AER-lncRNAs 
responded transcriptionally to estrogen stimulation in these 
experiments (Supplemental Table 1B). Moreover, four of 
these 31 AER-lncRNAs were regulated by ERα deletion 
in a direction that was not coherent with the effect of E2, 
i.e. Apo-ERα sustains basal expression, while E2-bound 
ERα represses it. This observation suggested that the 
AER-lncRNA set described here is specifically responsive 
to ERα deletion, rather than representing a simple 
subset of the estrogen-responsive signature. Therefore, 
we decided to address this point further. We examined 
DSCAM-AS1, LINC01016 and AP001057.1, which are 
robustly down-regulated by ERα siRNA (Figure 1C). 
These lncRNA genes display clear AERBS near their 
TSS or not far upstream (see above). By ChIP-qPCR 
analysis we observed a very significant increase in ERα 
binding to these three sites 45 minutes after E2 treatment 
(Figure 2A). On the contrary, time-course analysis of RNA 
expression by qRT-PCR after E2 treatment showed that, 
while LINC01016 increased 2.5-fold, in parallel with 
the well-known estrogen-regulated gene GREB1, neither 
DSCAM-AS1 nor AP001057.1 transcription responded 
to E2 over a period of 24 hours (Figure 2B). Especially 
in the case of DSCAM-AS1, which presents the AERBS 
very close to TSS, this may pose the question whether 
this site is the one responsible for the observed regulation 
after ERα silencing. To respond to this issue, we cloned a 
2 Kb fragment of the DSCAM-AS1 5′-flanking sequence, 
containing the observed AERBS, in a luciferase reporter 
vector and examined its activity in HEK 293T cells 
co-transfected with an ERα-expressing vector. As shown 
in Figure 2C, ERα expression induced a significant, 
though not dramatic, increase in luciferase expression, 
whereas notably no further response was elicited by three-
hour E2 treatment. Taken together, the above results allow 
defining DSCAM-AS1 as an ERα-regulated, but estrogen-
independent lncRNA gene.
We found further cases of incoherent response to 
ERα down-regulation or activation by E2 by comparing 
the effects of estradiol versus ICI 182,780 (“Fulvestrant”), 
which induces degradation of ERα protein (not shown). 
Taken together, this data suggests that AER-lncRNAs 
are a specific population of transcripts, which is in 
part distinguished from estrogen-regulated lncRNAs, 
representing a signature of unliganded ERα function in 
breast cancer cells.
AER-lncRNAs define Luminal subtype of breast 
cancer cell lines and tumors
The Affymetrix Human Genome U133 Plus 2.0 
microarray platform, used to measure the gene expression 
level of 1,037 cancer cell lines in the Cancer Cell Line 
Encyclopedia (CCLE) [28], contained probes for 38 AER-
lncRNAs. Exploring this resource, we found that a number 
of AER-lncRNAs are expressed in cancer cell lines of non-
breast origin. However, some of them, notably DSCAM-
AS1, LINC01016, LINC00925, KRTAP5-AS1, were 
quite specific to breast cancer cell lines (Supplemental 
Figure 2A).
Figure 2: Estrogen-independent expression of AER-lncRNAs. A. ChIP-qPCR analysis of ERα binding 45 minutes after E2 
treatment to DSCAM-AS1, LINC01016 and AP001057.1 AERBS-containing 5′-flanking regions (error bars are SD of three independent 
biological replicates); ***p-value < 0.001 and *p-value < 0.05. B. qRT-PCR analysis of GREB1 (positive control, red), LINC01016 
(orange), DSCAM-AS1 (dark-blue) and AP001057.1 (light-blue) expression in MCF-7 cells over a 24-hour time-course after E2 treatment 
(error bars are SD of three independent biological replicates); ***p-value < 0.001, **p-value < 0.01 and *p-value < 0.05. C. Luciferase 
reporter analysis of DSCAM-AS1 promoter in HEK 293T cells. Cells were transfected with 2Kb-DSCAMAS1p-Luc in combination with 
an empty pSG5 (light-grey bars) or ERα-expressing pSG5 vector (dark-grey bars), then grown in full medium (FM) or in hormone deprived 
medium minus (HD) or plus 10 nM E2 (3 h E2). Luciferase is expressed as firefly/renilla ratio and normalized to basal luciferase expression 
(error bars are SD of three independent biological replicates).
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More importantly, we asked whether AER-lncRNA 
expression is an ERα-dependent signature limited to the 
MCF-7 cell line or if it may represent a more general 
signature of luminal breast cancer. AER-lncRNA 
expression was evaluated using the data published on 
55 breast cancer cell lines [29], classified as luminal, 
basal, claudin-low and normal-like by the authors. 
Thirty-seven AER-lncRNAs revealed a significant 
differential expression (at least p-value < 0.001) in luminal 
versus non-luminal cells, the majority of them being 
overexpressed in luminal cells (Figure 3A). DSCAM-
AS1 was associated to the highest differential, i.e. log2 
fold change equal to 9.91 (Figure 3A). Importantly, 22 out 
of 28 lncRNAs up-regulated in luminal cells and seven 
out of nine down-regulated had concordant changes upon 
ERα silencing in MCF-7 cells, i.e. luminal-overexpressed 
are down-regulated, and vice-versa.
Next, we sought to identify an AER-lncRNA 
signature suitable to classify correctly breast cancer 
subtypes. As a first step, we verified if AER-lncRNA 
expression was able to classify breast cancer cell 
lines. Using a multi-layered perceptron classifier [30], 
we predicted cell line subtypes with an accuracy of 
96.36% (Supplemental Table 3). Then, we evaluated the 
relative contribution (also called merit) of each AER-
lncRNA to the classification, using the leave-one-out 
approach (Supplemental Figure 2B). Figure 3B shows 
the performance of clustering breast cancer cell lines: 
the first 29 AER-lncRNAs showing the highest merit 
(> 15) were extremely effective. Note that the right 
branch is composed by “pure luminal” cancer subtypes, 
and also non-luminal cell lines were correctly clustered 
with only one incorrect call (one basal-like clustered as 
normal-like). The fact that the whole AER-lncRNA set is 
a general luminal signature was confirmed by removing 
the 29 “high-merit” AER-lncRNAs. The remaining AER-
lncRNAs still classified correctly 80% of the cell lines 
(Supplemental Table 3). Next, we moved to validate 
this signature using an independent dataset of breast 
tumor biopsies. To this goal, we took advantage of data 
on 84 breast tumors from a published study [31], whose 
RNA-Seq data were downloaded and re-processed. This 
database contains only information concerning “Luminal” 
versus “Triple Negative” subtypes and we did not attempt 
re-classification. The 29-AER-lncRNA signature was very 
efficient in clustering tumor biopsies, with the left branch 
including pure “non-luminal” tumors and the right branch 
containing only one false call (Figure 3C). Principal 
Component Analysis (PCA) using this signature confirmed 
a clear separation of the samples (Supplemental Figure 
2C). This 29-AER-lncRNA signature clearly outperformed 
the clustering ability of the whole AER-lncRNA set both 
on cell lines (cf. Figure 3B with Supplemental Figure 2D) 
and on tumor biopsies (cf. Figure 3C with Supplemental 
Figure 2E).
Altogether, these results demonstrate that AER-
lncRNAs derived from MCF-7 cells represent a general 
luminal signature that can be used to discriminate breast 
tumor subtypes.
DSCAM-AS1 is a major discriminant of the 
luminal subtype in breast cancer cell lines and 
tumors
When examining AER-lncRNAs individually, 
DSCAM-AS1 outstands for several features. First, it had 
the highest value of RPKM among differentially expressed 
lncRNAs in MCF-7 (RPKM = 394 in siCTR condition, 
Supplemental Table 1A); second, it is characterized by 
the widest differential range of gene expression between 
luminal and non-luminal cell lines (log2 fold change = 
9.91) and, third, it showed significant correlation with 
ERα expression in both cell lines and tumor samples (see 
above). Finally, DSCAM-AS1 was already described 
in a cDNA library of MCF-7 cells subtracted with a 
benign cell line and designated as M41, and reported as 
expressed at higher levels in breast cancer than in normal 
tissue and benign lesions [32]. Therefore, we examined 
DSCAM-AS1 in deeper detail. First, we addressed the 
question whether DSCAM-AS1 is specific to cancer 
versus normal cells and, specifically, to breast cancer 
cells. Analysis of 6,249 RNA-Seq datasets extracted 
from the miTranscriptome database [11] demonstrated 
very low expression levels in normal tissues (Figure 4A), 
whereas elevated expression levels of DSCAM-AS1 
were found essentially in breast cancer tissues, with few 
overexpressing cases derived from lung, prostate and 
kidney carcinoma (Figure 4B). This fact was essentially 
confirmed using the CCLE microarray resource described 
above (Supplemental Figure 3A). Second, we asked 
whether DSCAM-AS1 expression was specific to breast 
cancer progression, by examining a recently published 
RNA-Seq dataset [33]. This study examined gene 
expression in Formalin-Fixed Paraffin-Embedded (FFPE) 
tissue samples, comparing normal tissues, pre-neoplastic 
lesions, in situ carcinoma (DCIS) and invasive carcinoma 
(IDC) from breast cancer patients, using the 3SEQ 
procedure, which determines the reads in the RNA region 
preceding the poly(A) tail. This approach is valid in the 
case of DSCAM-AS1, since all four described DSCAM-
AS1 transcripts have a common 3′ end (see below). As 
shown in Figure 4C, high levels of DSCAM-AS1 were 
observed only in overt carcinoma tissues, while it is 
almost undetectable in either the adjacent normal tissues 
or pre-neoplastic lesions. The difference between DCIS 
and IDC samples is not significant, albeit the box plot 
depicts a more regular distribution in DCIS than in IDC.
Next, we wanted to establish the relationship 
of DSCAM-AS1 expression to both ERα and breast 
tumor subtypes in a more robust way. We examined 
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Figure 3: A 29-AER-lncRNAs signature defines luminal subtype of breast cancer cell lines and tumors. A. Bar plot 
representing the differential expression of AER-lncRNAs in breast cancer cell lines of the luminal subtype as compared to cell lines of 
other subtypes (non-luminal). The most significant 37 lncRNAs are shown, plotting the relative prevalence as log2 fold change. Data from 
RNA-Seq analysis of 55 breast cancer cell lines were used [29]. B. Heat map illustrating expression values of the 29-AER-lncRNAs with 
highest classification “merit” (rows) in 55 breast cancer cell lines (columns) [29]. For each sample, the tumor subtype is color-coded below 
the dendrogram (basal-like = red, claudin-low = yellow, normal-like = green and luminal = blue), together with the Her2 status (positive = 
light blue; negative = white), and the ERα status (positive = light blue; negative = white). C. Heat map illustrating expression values of the 
29-AER-lncRNAs signature (rows) in 84 breast tumor tissue samples (columns) from published dataset [31]. Tumor classification is limited 
to “Luminal” and “Triple negative” and is indicated below the dendrogram with blue and red boxes, respectively. Values are expressed as 
log10 FPKM (Frequency Per Kilobase per Million fragments) and color-coded as indicated.
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Figure 4: DSCAM-AS1 is a major discriminant of the luminal subtype in breast cancer cell lines and tumors. A-B. Box 
plots showing DSCAM-AS1 expression in healthy (A) and neoplastic human tissues (B) extracted from the miTranscriptome RNA-Seq 
database [11]. For each tissue type, the number of samples where DSCAM-AS1 had a FPKM > 0 over the number of analyzed samples 
is reported in brackets. FPKM = Fragments Per Kilobase per Million mapped fragments. The red dotted line corresponding to log10 
(FPKM) = 0 is the cut-off value conventionally considered for calling as positive a lncRNA expression. C. Box plot reporting DSCAM-AS1 
expression in tissue samples normal, early neoplasia (EN), ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC) of the breast 
from a public dataset [33]; ***p-value < 0.0005 and **p-value < 0.005. D-E. Box plots showing DSCAM-AS1 expression in 839 breast 
tumor tissues, derived from the TCGA database [34]. In panel D tumor tissues are clustered as ERα-positive (Pos) and ERα-negative (Neg). 
In panel E the samples are classified as “adjacent normal tissue” or as tumor of the “basal”, “normal-like”, “HER2 positive”, “luminal A”, 
and “luminal B” subtype, accordingly to the PAM50 classifier. ***p-value < 0.00001. The p-values reported with color-coded stars refer to 
the comparison between luminal A and luminal B versus the other subtypes, as follows: Red = Adjacent normal; Orange = Basal; Ochre = 
Normal-Like; Light-green = HER2+. F. Bar plots reporting the differential expression of DSCAM-AS1 in the NextBio collection of breast 
cancer subgroups [35]. The significance of DSCAM-AS1 differential expression in each comparison is reported as -log10 (p-value). For 
each breast cancer bio-set, there is a brief description and the ID of the data (in brackets). Abbreviations are as follows: met = metastasis; 
dist. LN = distal Lymph Nodes; CNS = Central Nervous System; DC = ductal carcinoma; LC = lobular carcinoma; IDC = invasive ductal 
carcinoma; PR = Progesterone Receptor. G. Box plot showing the distribution of DSCAM-AS1 expression assessed by qRT-PCR in 42 
RNA samples derived from 16 ERα-negative (Neg) and 26 ERα-positive (Pos) breast tumor biopsies (IHC = immunohistochemistry; 
Supplemental Table 4); red circles are individual values, black circles the outliers; **p-value = 0.0021.
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the miTranscriptome data of 839 breast cancer tissues 
from the TCGA database [34] and found that DSCAM-
AS1 expression is significantly higher in ERα+ versus 
ERα- cases (p-value < 0.00001) (Figure 4D). Moreover, 
following the subtype classification of samples based 
on the PAM50 signature, it is possible to observe that 
Luminal A and -even more- Luminal B tumors express 
significantly higher levels of DSCAM-AS1 compared 
to adjacent normal tissues and tumors of the Basal and 
Normal-like subtypes (Figure 4E). Instead, HER2+ tumors 
show DSCAM-AS1 levels comparable to Luminal A.
Looking further to confirm these findings, we 
analyzed the differential expression of DSCAM-AS1 in 
the subgroup of breast cancer cases, defined by different 
clinicopathological features that are collected in the 
NextBio database [35]. All studies giving p-values of 
differential expression < 0.00001 are plotted in Figure 4F 
and Supplemental Figure 3B. In addition to confirming the 
clear association of DSCAM-AS1 expression in cancer vs 
normal breast, in ERα+ vs ERα-, and in luminal vs triple-
negative subtypes, we observed also higher DSCAM-AS1 
expression in tumors that are not metastatic vs metastatic, 
although not all the metastatic sites were considered in 
these studies. Only marginal association to positive 
axillary lymph nodes was observed.
This in silico data prompted us to further examine 
DSCAM-AS1 expression in a fresh series of breast cancer 
biopsies using qRT-PCR. To this goal, we designed PCR 
primer pairs spanning the constitutive last exon (see below 
and Figure 5A) and we ran qRT-PCR assays on 42 breast 
tumor samples (Supplemental Table 4). Quantitative data 
confirmed that DSCAM-AS1 expression is significantly 
higher in ERα+ breast cancer (Figure 4G), but no further 
correlation with other clinicopathological data was 
obtained. In conclusion, the AER-lncRNA DSCAM-AS1 
is a stage-specific marker of luminal breast cancer.
Preliminary characterization of DSCAM-AS1 
lncRNA
This data also prompted us to examine further traits 
of the DSCAM-AS1 gene and functions. DSCAM-AS1 
has four transcripts of length less than 2 Kb annotated in 
Gencode and Ensembl, differing mainly for the presence 
or absence of a central exon. The transcription unit is 
entirely contained, in antisense, in the third, 324 Kb 
intron of the DSCAM gene on chromosome 21 (Figure 
5A). By mapping data from several published studies 
(Supplemental Table 2) performed in MCF-7 cells in 
hormone-deprived medium, we obtained the functional 
representation of this region shown in Figure 5A. Apo-
ERα presents a bimodal peak close to DSCAM-AS1 TSS. 
The most proximal peak summit is a composite site bound 
by FoxM1, FoxA1 and AP-2γ transcription factors and, 
as in many other ERBSs, these TFs cooperate (see also 
Figure 1F).
We analyzed the expression of DSCAM-AS1 
isoforms in MCF-7 subcellular fractions by qRT-PCR 
using specific primers and confirmed that the isoform 
containing the central exon is mostly nuclear, while 
the other isoforms are cytoplasmic (Figure 5B). All 
four isoforms were similarly down-regulated after ERα 
silencing (Figure 5C), in keeping with a transcriptional 
effect. To further confirm the association of DSCAM-
AS1 expression with ERα, we analyzed ERα and 
DSCAM-AS1 RNAs in a panel of breast cancer cells 
by qRT-PCR, confirming that DSCAM-AS1 is confined 
to cells expressing ERα, with the exception of cells with 
HER2 amplification (SK-BR-3), as already noticed in 
previous in silico analysis (Supplemental Figure 3C). 
Interestingly, we observed complete down-regulation of 
DSCAM-AS1 in the T-47D-sfRon cell line as compared to 
parental cells. T-47D-sfRon were obtained by transducing 
T-47D cells with the oncogenic short form of the RON 
gene that caused complete loss of ERα expression and 
almost complete EMT [5, 36]. This further supports the 
conclusion that DSCAM-AS1 expression depends, at 
least in part, on the presence of ERα. Consequently, since 
experimental down-regulation of ERα leads, as a first 
evident consequence, to growth arrest in MCF-7 cells, we 
asked whether DSCAM-AS1 was essential for the growth-
sustaining action of unliganded ERα. We down-regulated 
DSCAM-AS1 expression using two different siRNAs, 
targeting the last exon common to the four transcripts. As 
shown in Figure 5D (left panels), siR_1 and siR_2 alone or 
in combination effectively down-regulated DSCAM-AS1 
RNA over a period of 72 hours after transfection. Bromo-
deoxyuridine incorporation was assayed at three-time 
points (24–48–72 hrs) after siRNA transfection and in all 
cases a significant reduction was observed when compared 
to cells transfected with control siRNA (Figure 5D, right 
panels). This reduction tended to increase with the time, 
in particular when hormone-deprived medium (HD) was 
used (Figure 5D, lower right panel) and reflected most 
likely both a decreased fraction of cells in S-phase and 
an increased cell death, as measured by FACS analysis 
(Supplemental Table 7). Notably, no significant change 
in ERα mRNA was noticed after DSCAM-AS1 silencing 
(Supplemental Figure 3D). DSCAM-AS1 siRNA also 
up-regulated mesenchymal markers N-Cadherin, Slug, 
Snail and Vimentin (Figure 5E), and induced partial 
morphological changes similar to what is observed after 
ERα down-regulation (not shown).
To get further insight on the possible function of 
DSCAM-AS1, we went back to the RNA-Seq data from 
55 breast cancer cell lines [29] used before, and ran a 
correlation analysis, in order to find which genes are most 
frequently co-expressed. By adjusting the correlation to 
an absolute value of r ≥ 0.7 and by applying a threshold of 
p-value = 0.001, 205 genes demonstrated significant co-
expression with DSCAM-AS1 (Supplemental Table 5A). 
We analyzed this co-expressed gene set using Ingenuity 
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Figure 5: DSCAM-AS1 lncRNA is functional to the basal ERα activity. A. Genome-browser view of the DSCAM-AS1 locus. 
DSCAM-AS1 (green; 1n = nuclear and 2c, 3c, 4c = cytoplasmic isoforms) is reported in association with Apo-ERα ChIP-Seq and RNA-Seq 
reads enrichment in siCTR- (violet) or siERα- (teal-blue) transfected MCF-7 cells; and with ChIP-Seq profiles of histone modifications 
(red), RNA-Pol II (orange) and seven TFs (yellow). Histograms are in Reads Per Million (RPM). B. DSCAM-AS1 isoforms expression 
by qRT-PCR in total, cytoplasmic and nuclear RNA fractions from MCF-7 cells. Isoforms are numbered in the same order as they are 
shown in the browser in (A). “n” and “c” indicate the nuclear or cytoplasmatic localization reported in the literature. 14S ribosomal RNA 
and U2 small nuclear RNA were used as fractionation controls. Error bars are SD of three independent biological replicates; ***p-value 
< 0.001. C. Effect of Apo-ERα down-regulation on DSCAM-AS1 isoforms by qRT-PCR. Error bars are SD of 3 independent biological 
replicates; **p-value < 0.01 and *p-value < 0.05. D. Left, DSCAM-AS1 expression measured by qRT-PCR in MCF-7 cells grown in full 
medium (FM, upper panels) or in hormone-deprived medium (HD, lower panels) and transfected with control siRNA (siCTR) or with 
two different siRNAs targeting DSCAM-AS1, alone (siR_1 and siR_2) or in combination (siR_1+2) (error bars are SD of 3 independent 
biological replicates); ***p-value < 0.001, **p-value < 0.01 and *p-value < 0.05. Right, MCF-7 cell proliferation, measured as BrdU 
incorporation (error bars are SD of 3 independent biological replicates); ***p-value < 0.001, **p-value < 0.01 and *p-value < 0.05. 
E. N-cadherin (N-Cadh), Slug, Snail and Vimentin (Vim) expression by qRT-PCR in MCF-7 cells grown in full medium (FM, upper 
panel) or in hormone-deprived medium (HD, lower panel) and transfected as in D (error bars are SD of 5 independent biological replicates); 
**p-value < 0.01 and *p-value < 0.05.
(Continued )
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Figure 5 (Continued ): F. Bar plot illustrating the functional analysis of genes whose expression is positively or negatively correlated with 
DSCAM-AS1 expression in RNA-Seq data of 55 breast cancer cell lines (29) (Supplemental Table 5A). The significance of Biological 
Functions enrichment (Supplemental Table 5B), as evaluated by Ingenuity Pathway Analysis, is expressed as -log10 (p-value). G. Bar 
plot reporting DSCAM-AS1 expression level in the 19 experiments from the GEO database reporting the effects of various treatments on 
MCF-7 cells, where DSCAM-AS1 was significantly down-regulated (p-value < 0.05). DSCAM-AS1 down-regulation is reported as -log2 
FC (fold change).
Pathway Analysis [37] and we observed that the most 
enriched terms were related to cell motility, adhesion 
and cancer cells invasion, further emphasizing a possible 
role of DSCAM-AS1 in the control of epithelial integrity 
(Figure 5F and Supplemental Table 5B).
To further corroborate this hypothesis, we analyzed 
107 microarray experiments of diverse experimental 
treatments of breast cancer cell lines present in Gene 
Expression Omnibus (Supplemental Table 2). From this 
analysis, we identified 19 treatments leading to significant 
DSCAM-AS1 down-regulation (at least p-value < 0.05). 
As illustrated in Figure 5G, the treatments leading to the 
most significant reduction of DSCAM-AS1 were those 
leading to EMT, i.e. Snail overexpression (GSE58252) 
and ERα silencing (GSE27473).
In conclusion, the function of DSCAM-AS1 
lncRNA appears related to cell survival and proliferation 
and to EMT, confirming a strict relationship of DSCAM-
AS1 with ERα in luminal breast cancer cells.
DISCUSSION
In this work, we describe a novel set of ERα-
dependent long noncoding RNAs that are mostly luminal-
specific and appear extremely promising in defining 
subclasses of breast tumors. In addition, we present 
preliminary studies on DSCAM-AS1 lncRNA that is 
the most closely associated to ERα expression in breast 
tumors and has possible functions in cell development 
and EMT.
Several groups have addressed lncRNA profiles in 
breast cancer either by examining tumor biopsies or in 
experimental settings. The novelty of our data relies on 
the experimental model system they were obtained from, 
i.e. transient silencing of ERα expression using MCF-7 
cells cultured in hormone-deprived media [4]. In other 
words, we have not addressed the transcriptional response 
of breast cancer cells to estrogen or other ligands, as many 
other published studies reported [16, 26, 27, 38], but to the 
basal activity of ERα, which represents the leading protein 
of Luminal A and B subtypes. Since the most common 
endocrine treatment today is Aromatase Inhibitors, which 
deplete the organism of estrogenic hormones, we believe 
that unliganded ERα action is extremely important to 
understand luminal breast tumor growth and progression. 
Albeit breast tumor cells often overexpress ERα, ERα 
binding to chromatin in absence of hormones has been 
reported in mouse uterus [39] an in other contexts [2, 3].
AER-lncRNAs do not appear simply as a 
miniaturized E2-responsive signature, since a significant 
fraction of AER-lncRNAs does not respond to estrogen, 
as we ascertained by data integration as well as 
experimentally. It should be also noted that our ERα-
dependent lncRNA set does not contain most of the 
lncRNAs that were previously studied in breast cancer, 
such as HOTAIR, CCAT2, UCA1, MALAT1, BCAR4, 
EGOT, SPRY4-IT1 and others [15, 17–24]. They show 
only limited overlap with other Luminal signatures [40, 
41]. Based on our analysis using datasets from both breast 
cancer cell line collections [29] and breast tumors [31], 
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this set contains a very powerful signature to distinguish 
not only luminal subtype, but also basal-like cancers.
AER-lncRNAs are regulated transcriptionally 
by ERα in a way that appears very like the same as for 
protein-coding gene, i.e. by remote enhancer elements. 
Indeed, we did not find evidence of enhancer-specific 
chromatin marks at AER-lncRNA TSS. In this respect, 
our results are different from those recently published 
by Sun and coworkers, who integrated GRO-Seq and 
RNA-Seq data to describe estrogen-induced lncRNAs in 
MCF-7 cells [16]. GRO-Seq experiments are much more 
sensitive to nuclear, short-lived transcript than steady-
state poly(A)+ RNA-Seq and will detect most of enhancer 
RNAs (eRNAs) induced by estrogen. Thus, our lncRNA 
set does not contain eRNAs and is more enriched of 
relatively stable lncRNAs, which is possibly an advantage 
for their use as cancer biomarkers.
In search of possible functions of AER-lncRNAs, 
we have started a preliminary characterization of 
DSCAM-AS1. It is quite astonishing that DSCAM-AS1, 
originally described by Liu and coworkers [32], has 
escaped the attention of many studies that have addressed 
lncRNA expression in breast cancer, especially due to 
the fact that, among all transcripts (protein coding and 
non-coding) DSCAM-AS1 classifies as the eighth most 
abundant RNA in luminal breast cancer cell lines (the 
first considering only lncRNA genes) and that it is neatly 
associated to ER-positivity. Perhaps the confounding 
effect of HER2+ tumors that also express DSCAM-AS1 
has led to disregarding. DSCAM-AS1 expression was 
recently described as differentially expressed also in lung 
adenocarcinoma [42].
The proximal AERBS that overlaps the DSCAM-
AS1 promoter (Supplemental Figure 4) may be involved 
in the regulation of DSCAM-AS1 transcription in ER+ 
breast cancer cells, as also suggested by our reporter 
assays (Figure 2C). This region contains a single ERE 
that is unusually close to the TSS (-26), corresponding to 
the proximal summit of the biphasic AERBS (Figure 5A 
and Supplemental Figure 4). Whether Apo-ERα directly 
regulates DSCAM-AS1 transcription by binding to this 
region awaits more direct proofs, such as measuring the 
effect of deleting the ERE or the use of DNA-binding 
defective ERα mutants. Furthermore, we do not know the 
mechanism leading to overexpression of DSCAM-AS1 
in HER2+ tumors and cell lines. In ER+/HER2+ cases, 
constitutive ERα activation through phosphorylation has 
been observed [3]. In absence of ERα, other transduction 
pathways may result in the transcriptional activation 
of DSCAM-AS1, perhaps targeting the other TFs that 
are present near DSCAM-AS1 TSS, as FoxM1, FoxA1 or 
AP-2γ. This point deserves further studies.
DSCAM-AS1 is antisense intronic within the 
DSCAM gene (Down Syndrome Cell Adhesion Molecule). 
Low levels of the coding DSCAM transcript are detectable 
in breast cancer cells, where it appears induced by 
estrogen [43]. Albeit the hypothesis of antisense/sense 
transcriptional control could be attractive, especially 
considering the fact that DSCAM encodes a protein 
important in cell adhesion, no function of DSCAM in 
mammary tissues has been described to date. Deletion 
of ERα also decreases slightly DSCAM mRNA with 
slow kinetics, concordant with DSCAM-AS1. However, 
silencing of DSCAM-AS1 does not affect DSCAM 
mRNA level (Supplemental Figure 3E). This data suggests 
that DSCAM-AS1 has its own function, independent of 
its host gene, in ERα+ breast cancer cells. Conversely, 
silencing of DSCAM-AS1 mimics some features of ERα 
silencing [4, 6] since it reduces cell growth, increases cell 
death and induces EMT markers without influencing ERα 
expression. This is suggestive of a function of DSCAM-
AS1 downstream ERα that is probably limited to breast 
carcinoma development. However, further studies are 
needed to fully understanding DSCAM-AS1 function. 
The lack of conservation of DSCAM-AS1 below Primates 
would render it difficult to assess its role, if any, in 
mammary gland development.
Analysis of possible functions was made by 
examining the correlation of gene expression between 
AER-lncRNA and protein-coding genes in published 
studies. This is an inductive way of considering function 
association and, of course, it should be validated by 
more direct approaches, such as lncRNA deletion or 
ectopic expression. Nevertheless, it is intriguing that 
DSCAM-AS1 expression is inversely correlated with 
genes with function in cell motility. This may explain 
why DSCAM-AS1, albeit clearly associated to neoplastic 
growth, is very high in ductal carcinoma in situ, whereas 
its expression may be reduced when cells escape cell-to-
cell contacts, undergo EMT and acquire invasiveness. 
This is also proven by the fact that down-regulation of 
DSCAM-AS1 in MCF-7 cells led to increased expression 
of mesenchymal markers. Clearly, further work is needed 
to fully understand the functions of DSCAM-AS1, as 
well as other AER-lncRNAs, and to establish whether 
DSCAM-AS1 may mediate some of the functions of 
unliganded ERα.
Overall, ERα+ breast tumors (Luminal A and B) 
respond well to endocrine treatments at both the adjuvant 
and advanced settings. Nonetheless, one-fourth of these 
cases present either primary resistance or acquired 
resistance during treatment. This makes development 
of new markers and targets an important challenge [8]. 
The set of ERα-dependent, luminal-specific lncRNAs 
presented here will be further studied as possible markers 
and targets. One of these, the carcinoma-specific DSCAM-
AS1, is particularly interesting since it is functional 
to ERα action, but does not respond to estrogen, thus 
representing an ideal marker of ERα function in absence 
of hormones.
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MATERIALS AND METHODS
Cells culture
MCF-7, HEK 293T, MDA-MB-231 and SK-BR-3 
cells were routinely grown in DMEM (Life Technologies, 
31053–028); T-47D, T-47D-sfRON and ZR-75–1 cells 
were grown in RPMI (Life Technologies, 31870–025) and 
HTERT-HME1 cells were grown in DMEM/F12 (Life 
Technologies, 21041–025). All media were supplemented 
with 10% heat-inactivated FBS (Biochrom, S0115–1), 
2 mM L-glutamine (Life Technologies, 25030–024), 
50 U/ml penicillin and 50 μg/ml streptomycin (Life 
Technologies, 15140–122) and only in DMEM/F12 
was added 1x mammary epithelial growth supplement 
(containing bovine pituitary extract, bovine insulin, 
hydrocortisone and recombinant human epidermal growth 
factor). Hormone-deprived medium (HD) was obtained 
from phenol red-free DMEM (Life Technologies, 31053–
028) supplemented with 5% charcoal-dextran-treated 
serum. 17β-estradiol (E2) (Sigma, E2758–1G) was added 
at a final concentration of 10 nM. Batches of human cell 
lines were purchased from ATCC. Cell culture was at 37°C 
with 5% CO2.
Small interfering RNA (siRNA)
MCF-7 cells were grown both in full medium (FM) 
and in hormone-deprived (HD) medium before being 
transfected with siRNAs (20 nM final concentration) 
using Lipofectamine2000 (Life Technologies, 
11668–019), according to the manufacture’s protocol. 
Stealth RNAiTM siRNAs from Life Technologies 
were used to target ERα mRNA [4]; custom-
designed Stealth siRNAs from Life Technologies 
were used to target DSCAM-AS1 lncRNA (siR_1: 
5′-ACUCAUCCAUGUACCCAUUUCUUAA-3′ and 
siR_2: 5′-CCUCCUCCAACUGCCAUUUAUUUAU-3′); 
stealth RNAi™ siRNA Negative Control Med GC was 
used as a control (siCTR; Life Technologies, 12935–300). 
Unless otherwise specified, experiments were performed 
48 hours after siRNA transfection.
RNA isolation and quantitative Real-time PCR 
(qRT-PCR)
RNA was isolated from MCF-7 cells using the 
Trizol™ reagent (Life Technologies, 15596–026). 
Nuclear and cytoplasmic RNA fractions were obtained 
from MCF-7 cell pellets by lysis in 10 mM TRIS pH = 
7.8, 140 mM NaCl, 1.5 mM MgCl2, 10 mM EDTA, 0.5% 
MP40 and 0.3U RNase inhibitor (Life Technologies, 
AM2694) for 5 min on ice and centrifugation at 3,000 x g 
for 3 min to obtain a cytosolic fraction and nuclear pellet, 
followed by Trizol™ extraction. Frozen breast cancer 
tissues (previously collected and stored at − 80°C) were 
directly homogenized in Trizol™ to extract total RNA. 
All total RNA samples were subjected to DNase treatment 
to remove contaminating genomic DNA (DNA-free@ 
DNA removal kit, Life Technologies, AM1907). First 
strand cDNA synthesis was performed with a M-MLV 
reverse transcriptase Kit (Life Technologies, AM2044-
AM5722G-AM8228G. qRT-PCR analysis was performed 
using the SYBR-green method (iTaq UniverSYBR 
Green, Biorad, 1725124). Real-time PCR primers 
for human 18S (QT00199367), ERα (QT00044492), 
GREB1 (QT00080262), N-cadherin (QT00063196), 
SLUG (QT00044128) and SNAIL (QT00010010) RNAs 
were purchased from Qiagen (QuantiTect@ Primer 
Assay). Custom expression-primer pairs are reported in 
Supplemental Table 6.
Chromatin immunoprecipitation assay (ChIP)
MCF-7 cells were grown for 2 days in HD medium 
before siRNA transfection or 17β-estradiol (E2) treatment. 
ChIP experiments were performed as described in 
[4]. qRT-PCR was carried out on ChIP-enriched DNA 
using SYBR Green Master Mix. ChIP enrichment was 
normalized on input samples (1% of total chromatin used 
per IP) and expressed as enrichment of specific binding 
over the control unspecific IgG binding. Antibodies 
against human ERα (Santa Cruz Biotechnology; sc534X, 
sc7207X), AP-2γ (Santa Cruz Biotechnology; sc-8977X), 
FoxA1 (Abcam; ab5089) and IgG (Abcam, ab46540) were 
used in this assay. Custom ChIP-primer pairs are reported 
in Supplemental Table 6.
DSCAM-AS1 promoter cloning and promoter-
activity assay
A BAC carrying a 25 Kb region of the human 
chromosome 21 (Life Technologies; clone ID: 3214D4; 
Chr21:41739181–41764048 genomic region) was used as 
DNA template for the DSCAM-AS1 promoter amplification 
by high-fidelity PCR amplification (HiFi-Taq@ polymerase 
kit, Life Technologies, 11304–011). We amplified a 2 Kb 
sequence including approximately 170 bp sequence 
downstream to DSCAM-AS1 TSS and 1,830 bp sequence 
upstream, by using the following primers:
• 2 Kb promoter Fwd: 5′-CCGCTCGAGCCTTTATAGAGA-
TATGGAAAGGGGA-3′
• 2 Kb promoter Rev: 5′-CCCAAGCTTGTTCCAG-
CATTTCTCCTGC-3′
The amplified sequences were then purified and 
directionally cloned into pGL3-Basic-Luc (firefly) reporter 
vector (pGL3 Basic, Promega, E1751). Competent 
bacterial cells were used to amplify the obtained 2Kb-
DSCAMAS1p-Luc vector. HEK 293T cells were 
transfected with the basal pGL3-Basic-Luc vector or the 
2Kb-DSCAMAS1p-Luc vector and with pGL4-renilla 
vector (pGL4.73 [hRluc/SV40] Vector, Promega), as 
internal control of transfection efficiency, in combination 
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with pSG5 empty or pSG5-hERα expressing vector 
(pHEGO vector, [44]). To assay for DSCAM-AS1 
promoter activity, firefly luciferase mRNA production was 
evaluated by qRT-PCR, as firefly/renilla luciferase mRNA 
expression ratio, in FM, HD or 10 nM E2 treatment 
culture conditions, and was then normalized on the firefly/
renilla luciferase mRNA expression ratio from pGL3 basic 
vector. Custom expression-primer pairs are reported in 
Supplemental Table 6.
Cell proliferation assay and FACS analysis
Cell proliferation rate was assayed by measuring 
BrdU incorporation in a 2-hours pulse by the use of 
an ELISA format, according to Cell Proliferation Kit 
instructions (GE Healthcare Life sciences, RPN250).
FACS analysis was performed 48 hours after 
siRNAs transfection. Growth media and cells were 
harvested and fixed with 70% cold ethanol. Sample pellets 
were treated with 100 μg/ml RNase A (Qiagen, 19101) for 
15 minutes at RT and then were incubated with 50 μg/ml 
Propidium Iodide (PI) for 2 hours at 4°C, protected from 
light. The DNA content of the cells, labeled with PI, was 
analyzed using a Cyan ADP flow cytometer (Beckman 
Coulter, Brea, CA, USA).
RNA-Seq data analysis and identification of  
Apo-ERα regulated lncRNAs
AER-lncRNAs list was defined by analyzing our 
previously published RNA-Seq experiment performed 
in MCF-7 cells that were grown in HD medium and 
transfected with control (siCTR) or targeting-ERα (siERα) 
siRNAs (GSE535353). For RNA-Seq analysis, the 
strategy used in [4] was repeated using Gencode v19 as 
transcriptome reference and hg19 assembly (GRCh37) as 
genome reference. The final set of Differentially Expressed 
(DE) lncRNAs was defined by considering a transcript 
length threshold of 200 bp and by excluding pseudogenes 
and ambiguous annotations reported as discordant 
entries (i.e. both protein coding and noncoding gene) 
between Ensembl (version 75) and RefSeq (version 64) 
(e.g. SEMA3B, SSPO, CYP4F8, LEPREL2, TRAV39). 
DESeq-normalized read counts were converted to Reads 
per Kilobase of Exon per Million Reads Mapped (RPKM) 
using the longest-isoform length (in Kb) and the million 
number of reads counted by HTSeq (63.63 and 61.31 
million in siCTR and siERα condition, respectively).
Computation of distances between DE lncRNAs 
and Apo-ERBSs
Distances between the TSS of lncRNAs and 
the center of Apo-ERα Binding Sites (AERBS; [4]) 
were computed by using an ad-hoc Perl script and by 
establishing 1,000 Kb as maximum distance-threshold. 
One thousand random sets of lncRNAs with the same 
composition in biotypes were used as control sample. 
The differences in distances distribution were statistically 
evaluated using the Wilcoxon Rank-Sum test.
Computational analysis of public ChIP-Seq 
datasets
ChIP-Seq signals of RNAPII, H3K4me3, H3K4me1, 
H3K27ac and p300, were analyzed in a genomic window 
of ± 1 Kb around the TSS of DE lncRNAs and protein 
coding genes.
The AERBSs mapped within 100 Kb from TSSs of 
both lncRNAs and protein coding genes were analyzed 
for ChIP-Seq signal of AP-2γ, c-Myc, CTCF, FoxM1, 
FoxA1 and Gata3. From each study raw sequencing data 
were aligned with Bowtie v2.1.0 [45] in default settings; 
ChIP-Seq reads were counted with Seqminer [46] by 
considering 50 bp bins and 200 bp reads extension. Read 
counts were converted in Count Per Million (CPM) using 
the number of reads in each experiment. Only experiments 
performed in vehicle-treated MCF-7 were considered. See 
Supplementary Table 2 for the list of the dataset used.
Computational analysis of public gene-
expression datasets
GRO-Seq datasets
Raw data of vehicle or E2-treated MCF-7 for 10, 25, 
40 and 60 minutes (GSE43835, GSE41324, GSE45822) 
were aligned with Bowtie v2.1.0 and aligned reads were 
counted with HTSeq [47]. Differential expression between 
vehicle and E2-treatment conditions was performed using 
DESeq v1.2.0 [48]. Genes associated with a p-value 
< 0.05 in at least one time-point were considered as 
differentially expressed. If multiple replicates in the same 
time-point were available the fold changes were averaged 
and the p-values combined using metaRNASeq R package 
[49].
CCLE
Normalized data from Cancer Cell Line 
Encyclopedia (CCLE) project [28] were downloaded from 
the project website (http://www.broadinstitute.org/ccle). 
The gene-identifier associated to each probe was updated 
to Ensembl 75 annotations and the expression levels of 
multiple probes were averaged if associated to the same 
gene. The expression values of each probe across all cell 
lines were converted to Z-Score by subtracting the mean 
and dividing by standard deviation.
RNA-Seq datasets
Public raw data of 55 breast cancer cell lines 
(GSE48213) and 84 breast cancer tissues (GSE58135) 
were aligned with Tophat v2.0.0 [50] and the reads were 
counted with HTSeq. Table of counts were normalized 
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using DESeq and then converted to FPKM values. 
Molecular and clinical information about cell lines 
and tissues analyzed were obtained from information 
provided by authors. Considering the 55 cell lines from 
GSE48213, a differential expression between luminal and 
non-luminal subtypes was performed using DESeq v1.2.0. 
Unsupervised hierarchical clustering was performed using 
heatmap.2 R function with Ward.D2 method while PCA 
analysis using prcomp R function.
3SEQ datasets
Data of 72 breast cancer tissues at different disease 
stages (GSE47462) were aligned with Bowtie v2.1.0 and 
reads counted with HTSeq. Molecular and clinical details 
were obtained from information provided by authors.
miTranscriptome database
Analysis of DSCAM-AS1 expression in 6,249 RNA-
Seq experiments on tissue samples from miTranscriptome 
[11] was performed retrieving the lncRNA FPKM 
expression from project website (mitranscriptome.org). An 
average FPKM was computed among expression levels 
computed for the four DSCAM-AS1 isoforms.
Microarray datasets
Analysis of DSCAM-AS1 expression in published 
microarray experiments of breast cancer specimens was 
performed using NextBio web tool [35]. Only bio-sets 
associated with p-value < 0.00001 were considered. 
Microarray experiments performed in breast cancer 
cell lines using Affymetrix Human Genome U133 Plus 
2.0 platform were analyzed with GEO2R. Only those 
experiments with at least two biological replicates were 
analyzed.
Unsupervised lncRNA selection by Weka
To identify a list of lncRNAs discriminating 
breast cancer subtypes, a machine-learning classification 
approach using Weka 3.6.12 [30] was applied. The four 
subtypes of breast cancer cell lines (luminal, basal, 
claudin-low and normal-like) were used as class label to be 
identified based on the expression of AER-lncRNA genes. 
Classification was performed with a MultilayerPerceptor 
classifier with ten folds cross-validation. The contribution 
of each lncRNA on the classification results was evaluated 
using Weka ChiSquareAttributeEval function with ten folds 
cross-validation. This method is based on the computation 
of a Chi-squared statistic for each attribute of the input 
(lncRNA) with respect to the class labels (i.e. breast cancer 
subtype). The larger the Chi-squared, the more relevant is 
the feature with respect to the class. The Chi-squared is 
used to compute the average merit of each lncRNA.
DSCAM-AS1 guilt-by-association analysis
To identify a list of DSCAM-AS1 correlated and 
anti-correlated genes, data from RNA-Seq experiments of 
55 breast cancer cell lines (GSE48213) were considered to 
compute a pairwise Pearson correlation between expression 
of DSCAM-AS1 and all Gencode v19 genes. Only genes 
associated to an absolute r >= 0.7 and correlation p-value 
< 0.001 were retained. These genes were subjected to 
QIAGEN’s Ingenuity Pathway Analysis (IPA) [37].
Transcription Factor Binding Sites (TFBSs) analysis
TFBSs analysis on the DSCAM-AS1-promoter 
AERB was performed by using MATCH™ algorithm in 
default settings [51].
Statistical analysis
For proliferation, ChIP-qPCR and gene-expression 
(qRT-PCR) data the standard deviation (SD) was computed 
among independent experiments and the t-test was used to 
compute the p-values. DSCAM-AS1 expression in breast 
cancer tissue samples was evaluated in two different 
runs (N = 22; N = 20). In order to merge the data, values 
were computed as ΔCt from qRT-PCR (18S Ct/DSCAM-
AS1 Ct). Values of the two series were then ranked, 
log-transformed (in order to deal with non-normality 
of the data) and regressed over the values of series 1. 
A bootstrap approach with 200 iterations was applied in 
order to minimize the estimated mean square error. Then, 
the estimates of the regression model were used to adjust 
the log-transformed values of the Series 2 according to the 
location and scale parameters of log-transformed values of 
the Series 1. Finally, they were back-transformed on the 
original scale. Wilcoxon Rank-Sum test was used to assess 
differences between sample 1 and sample 2, Shapiro-Wilk 
test was applied to assess data normality.
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